Expert Interview
Examining the Phase 3 topline results from Intra-Cellular's study 502 looking at Lumateperone in patients with major depressive disorder
Ticker(s): ITCIInstitution: Massachusetts General
- Director of the Neurotherapeutics Division in the Department of Psychiatry at MGH and the Director of the Mood Disorders at Massachusetts General Hospital Psychiatric Neuroimaging Group
- Treats 30 patients for PPD
- Research focuses on neurotherapeutic interventions for severe, treatment-resistant psychiatric illnesses, particularly for post-traumatic stress disorders, eating disorders, major depressive disorder and obsessive compulsive disorder
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
